Establishment of a Predictive System for Perioperative Risk Assessment and Electronic Flowcharting Response Strategies in Thoracic Surgery
Launched by HENGXING LIANG · Aug 20, 2024
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients admitted to the Department of Thoracic Surgery of the Second Xiangya Hospital of Central South University for surgical treatment.
- Exclusion Criteria:
- • Patients admitted to the Department of Thoracic Surgery of the Second Xiangya Hospital of Central South University without surgical treatment.
- • Patients under the age of 18.
About Hengxing Liang
Hengxing Liang is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and rigorous methodologies. With a focus on enhancing therapeutic strategies across various therapeutic areas, Hengxing Liang leverages a collaborative approach, working closely with healthcare professionals, regulatory bodies, and research institutions. The organization prioritizes ethical standards and patient safety, ensuring that all trials are conducted with the highest level of integrity and compliance. Through its comprehensive portfolio of clinical trials, Hengxing Liang aims to contribute valuable insights to the scientific community and facilitate the development of groundbreaking treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Changsha, Hunan, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported